# EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma

> **NCT02601937** · PHASE1 · COMPLETED · sponsor: **Epizyme, Inc.** · enrollment: 109 (actual)

## Conditions studied

- Rhabdoid Tumors
- INI1-negative Tumors
- Synovial Sarcoma
- Malignant Rhabdoid Tumor of Ovary

## Interventions

- **DRUG:** Tazemetostat

## Key facts

- **NCT ID:** NCT02601937
- **Lead sponsor:** Epizyme, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-01-07
- **Primary completion:** 2021-06-19
- **Final completion:** 2021-10-22
- **Target enrollment:** 109 (ACTUAL)
- **Last updated:** 2024-10-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02601937

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02601937, "EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02601937. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*